Table 2.
Sustained Virologic Response Rates (95% Confidence Intervals) in 15,884a Patients Who Initiated Antiviral Treatment in the Veterans Affairs Nationally From January 2014 to June 2015
| Genotype 1, SVR, % (95% CI)
|
Genotype 2, SVR, % (95% CI)
|
Genotype 3, SVR, % (95% CI)
|
Genotype 4, SVR, % (95% CI)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | All patients | LDV/SOF | LDV/SOF+RIBA | PrOD | PrOD+RIBA | SOF+RIBA | LDV/SOF+RIBA | SOF+PEG+RIBA | SOF+RIBA | LDV/SOF±RIBA | PrOD±RIBA | |
| n | 15,884 | 7412 | 2500 | 704 | 2128 | 1910 | 344 | 131 | 630 | 97 | 28 | |
| All patients | 15,884 | 90.7 (90.2–91.1) | 92.9 (92.2–93.3) | 92.0 (90.9–93.0) | 94.9 (92.9–96.3) | 92.5 (91.3–93.5) | 86.2 (84.6–87.7) | 77.9 (73.1–82.0) | 87.0 (80.0–91.8) | 70.6 (66.9–74.1) | 87.6 (79.3–92.9) | 96.4 (76.3–99.5) |
| Patients who completed | ||||||||||||
| 8-wk treatment | 2027 | NA | 94.3 (93.2–95.3) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 12-wk treatment | 9921 | 94.0 (93.5–94.4) | 95.0 (94.3–95.7) | 92.9 (91.7–94.0) | 98.1 (96.7–99.0) | 96.3 (95.3–97.1) | 90.9 (89.3–92.4) | 82.6 (77.6–86.7) | 88.9 (80.9–93.8) | NA | 97.0 (88.5–99.3) | 100 |
| 24-wk treatment | 1383 | 88.1 (86.3–89.7) | 94.6 (92.7–96.1) | 95.8 (90.9–98.1) | NA | 100 | NA | NA | NA | 76.1 (72.0–79.7) | NA | NA |
| SVR in the following subgroups | ||||||||||||
| No cirrhosis | 11,111 | 92.3 (91.8–92.8) | 93.5 (92.8–94.1) | 95.6 (94.1–96.7) | 94.8 (92.8–96.3) | 92.1 (90.6–93.5) | 89.1 (89.1–90.6) | 84.8 (79.4–88.9) | 93.4 (83.4–97.6) | 77.6 (72.9–81.6) | 90.3 (80.7–95.4) | 95.5 (70.4–99.5) |
| Cirrhosis | 4773 | 86.8 (85.8–87.7) | 90.5 (88.9–91.9) | 89.4 (87.7–90.9) | 95.7 (83.8–99.0) | 93.4 (91.1–95.1) | 77.3 (73.3–80.8) | 65.3 (56.3–73.3) | 81.4 (70.3–89.0) | 61.9 (56.0–67.4) | 80.0 (58.3–92.0) | 100 |
| FIB-4 score ≤3.25 | 9695 | 92.5 (92.0–93.0) | 93.7 (93.0–94.3) | 93.7 (92.1–95.0) | 95.2 (93.1–96.6) | 92.2 (90.6–93.5) | 89.2 (87.3–90.9) | 85.6 (79.4–90.2) | 92.9 (82.0–97.4) | 80.4 (74.9–84.9) | 90 (80.2–95.2) | 95.5 (70.4–99.5) |
| FIB-4 score >3.25 | 5418 | 87.4 (86.7–88.3) | 90.9 (89.6–92.1) | 90.7 (89.0–92.2) | 92.6 (84.2–96.7) | 93.1 (90.9–94.8) | 80.8 (77.6–83.7) | 69.0 (61.2–75.9) | 81.0 (69.0–89.0) | 62.7 (57.5–67.7) | 80.8 (59.6–92.3) | 100 |
| Treatment-naïve | 11,159 | 91.1 (90.6–91.6) | 92.7 (92.0–93.4) | 92.9 (91.2–94.3) | 95.8 (93.8–97.2) | 92.0 (90.6–93.3) | 88.0 (86.3–89.6) | 78.1 (72.3–82.7) | 90.6 (80.3–95.9) | 75.1 (70.8–79.0) | 86.1 (75.8–92.5) | 95.5 (70.4–99.5) |
| Treatment-experienced | 4725 | 89.7 (88.7–90.5) | 93.2 (91.9–94.3) | 91.4 (89.8–92.7) | 91.4 (85.7–95.0) | 93.8 (91.4–95.5) | 80.2 (76.2–83.6) | 77.4 (67.0–85.2) | 83.6 (72.4–90.8) | 61.1 (54.0–67.6) | 92.0 (70.9–98.2) | 100 |
NA, not available.
a
The number of patients is different from that in Table 1 because Table 2 includes only 15,884 patients with available SVR data (of 17,487 patients who initiated antiviral treatment).